Study for Prevent Chronification Migraine Through Prediction of Response to Treatment With Anti-CGRP Antibodies

Korábbi kezelés

• Patients who present with another type of non-migraine headache, with the exception of headache due to excessive use of analgesic medication.
• Patients who require changes in preventive treatment during the first 6 months after starting treatment with monoclonal antibodies.
• Patients who present any significant adverse effect that requires withdrawal or change of anti-CGRP drug.

Egyéb

• Neurological focus in the examination.
• Pregnancy or breastfeeding period.
• Patients with cognitive deficiency or pathology that may prevent or hinder the correct completion of the study.

• Patients aged between 18 and 65 years.
• Caucasian ethnicity.
• Patients diagnosed with migraine with and without high-frequency episodic aura (more than 8 days of migraine per month) or chronic by a neurologist expert in headaches and according to the criteria proposed in the International Classification of Headache Diseases, 3rd edition (ICHD- 3).
• Have at least one year of history of migraine.
• Patients must maintain stable preventive treatment in the previous month and not have received botulinum toxin in the month prior to starting the monoclonal antibody.
• Patients able to describe their clinical situation and the characteristics of their headache.
• Grant your informed consent.